MedTrace Logo

A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.

NCT06733311 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2024-12-13

No results posted yet for this study

Summary

Brief Summary:

The goal of this observational study is to develop a non-invasive urine proteomic diagnostic model to improve early-stage lung cancer detection. The study aims to answer the following main questions:

Can urine proteomics reliably differentiate early-stage lung cancer from benign conditions? How does the diagnostic model compare to current clinical and imaging methods in accuracy?

Participants will:

Provide preoperative urine samples. Undergo proteomic analysis of urine samples. Have clinical, imaging, and proteomic data integrated into an AI-assisted diagnostic model.

The study will evaluate the sensitivity and specificity of this innovative diagnostic approach.

Conditions

Sponsors & Collaborators

  • Beijing Chao Yang Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06733311 on ClinicalTrials.gov